The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1288
A Fixed-Dose Combination of Sumatriptan and Naproxen for Migraine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved an oral, fixed-dose combination (Treximet – GlaxoSmithKline) of the selective serotonin receptor agonist (“triptan”) sumatriptan (Imitrex) and the nonsteroidal anti-inflammatory drug (NSAID) naproxen sodium (Anaprox, and others) for acute treatment of migraine attacks. Imitrex tablets are expected to go off-patent in February 2009.

STANDARD TREATMENT — Mild or moderate episodes of migraine are often treated with nonopioid analgesics such as aspirin or acetaminophen, used alone or in combination with caffeine, butalbital and other drugs. A combination of aspirin, acetaminophen and caffeine (Excedrin Migraine) is available over the counter (OTC). The NSAID ibuprofen in a dose of 200 mg (Advil, and others) is FDA-approved for OTC treatment of migraine, and other NSAIDs, including naproxen, have been used as well.

For moderate to severe ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Fixed-Dose Combination of Sumatriptan and Naproxen for Migraine
Article code: 1288a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian